Yang Danxu Beijing Special Commissioner
The crown disease of China Biopharmaceutical Beijing Corporation of China National Pharmaceutical Group was approved for listing.Chinese officials said they would provide a free crown vaccine for the whole people.
This is the first domestic coronary vaccine approved by China.Chen Shifei, deputy director of the State Drug Administration, said at a press conference yesterday that the known and potential benefit of this vaccine of Chinese medicine (Sinopharm) is greater than the risks of known and potential, which fully reaches the preset attachment.Condition listing standards ".
However, the official will urge enterprises to continue the three -phase clinical trials in accordance with the plan, and require companies to update, supplement vaccine instructions, labels in timeWait, and apply to the regulatory authorities for approval or declare filing.
There are 14 coronary vaccines in China entering clinical trials, five of which have entered the third phase of clinical trials.This lively vaccine from Beijing Company and other leading vaccines have been approved in China. It has been approved in China. It means that it can be available for large -scale vaccination.
Zeng Yixin, deputy director of the National Health and Health Commission and the research and development of the research and development of the scientific research and development group of the State Council ’s joint defense and control mechanism, introduced that China will be inoculated in an orderly manner to promote the elderly and high -risk groups with basic diseases, and then start other general groups.Out of inoculation.
China has carried out emergency vaccinations on high -risk people since mid -last year, and launched a key population from December 15th. So far, it has accumulated more than 4.5 million doses.
Zeng Yixin does not deny that a certain percentage of adverse reactions occur during vaccination. "The total incidence is close to the several types of inaccession vaccines ... The case of mild fever is about 0.1 %.The incidence of adverse reactions is about 2 %. "
In response to the price of vaccine, Zheng Zhongwei, the leader of the research and development working group of the State Council ’s joint defense and control mechanism, said in response to the Lianhe Zaobao question that the enterprise must follow the attributes of public product when pricing for the vaccine.Taking cost as the basis for pricing. "
vaccine pricing will be in "People can accept the range"
He explained that the cost of vaccine is closely related to production scale and use scale. As the vaccination work is pushed open, the cost will be greatly reduced, and the price "must be within the range that ordinary people can accept."
Zeng Yixin then added: "The basic attributes of the vaccine are still public products, and the price may change according to the size of the use scale, but a major premise is that it must be provided for free for the whole people."
Earlier in some parts of China launched a crown disease vaccine emergency vaccination, the price of 200 yuan (about S $ 40) was priced at each needle.
Approval of coronary vaccine is listed, showing that China is determined to become a major vaccine provider in the country and countries in the world, but the transparency of Chinese developers' transparency in the release of clinical data in the third phase of the third phase of the third phase of the clinical data has been questioned.Challenge above.
The Beijing Company announced the day before yesterday that the company's crown disease is 79.34%, but more test data was not announced.
Wu Yonglin, president of the Chinese Medicine, introduced at the same conference yesterday that the vaccine conducted three -phase clinical trials in many countries such as the UAE and Barin, with more than 60,000 people in vaccination.He said that detailed data will be announced later and will also be published in scientific research magazines at home and abroad.
79%of the efficiency is lower than Pfizer and Biontech, as well as vaccines developed by Moderna.Both of these two vaccines are more than 90 %, but they are new MRNA vaccines.
Compared with China's vaccine and foreign vaccines, Zheng Zhongwei said: "I don't think it can be simply evaluated, because the vaccines of each route have their own advantages ... Only comprehensively determine the safety, effectiveness, validity, and availability of each vaccine.Only in order to scientifically evaluate this vaccine. "
